Debiopharm GroupTM (Debiopharm), a Swiss-based global biopharmaceutical group of companies has decided to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its industrial development and production facility in Martigny (Valais, Switzerland), through acquisition of industrial high-value added activities or companies in the pharmaceutical, biotech or medtech field.
Debiopharm Research & Manufacturing S.A. boasts 35 years of expertise in drug development including chemical synthesis, formulation improvement and manufacturing. Major investments have been made since 2007 to automate the facility and increase its industrial capacity. The objective is to expand industrial operations in Martigny by acquiring opportunities for optimization and production, generating a double-digit million revenue annually. Expertise in R&D and manufacturing of hard-to-make pharmaceutical products, modern infrastructure combined with high-tech GMP-compliant production, a logistic platform for worldwide delivery, established quality assurance and regulatory certification, as well as a central location in Europe are some of the features that will enable this objective to be met.
"We want to be the bridge between development and industrialization," says Cedric Sager, Chief Executive Officer of Debiopharm Research & Manufacturing S.A., "and supply Swiss-made products manufactured using state-of-the-art technology. Hard-to-make drugs, highly complex formulated drugs, biologic niche products, premium diagnostics and medical devices are on our wish-list."
Thierry Mauvernay, Delegate of the Board of Debiopharm Group, explains that "we have invested heavily during the last years to automate our site in Martigny as much as possible. Thanks to our efforts, we have increased our productivity. Our wish now is to acquire new industrial opportunities to strengthen our activity in Valais and support our development".
Source: PR Newswire
Click here for the complete issue.